Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Royer

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Obesity (Silver Spring, Md.)|December 1, 2006
ABCA1 single nucleotide polymorphisms on high-density lipoprotein-cholesterol and overweight: the D.E.S.I.R. studyIsabelle Porchay, Franck Péan, Naïma Bellili, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2021
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patientsNastja Lunar, Marie-Christine Etienne-Grimaldi, Pauline Macaire, et al.
Anti-Cancer Drugs|September 16, 2005
Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein bindingBernard Royer, Emmanuel Guardiola, Emmanuel Polycarpe, et al.
Anti-Cancer Drugs|December 25, 2009
Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I studyEmmanuel Guardiola, Bruno Chauffert, Delphine Delroeux, et al.
Seminars in Oncology|September 20, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincingMarie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, et al.
Anti-Cancer Drugs|September 22, 2010
Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumorsAntoine Thiery-Vuillemin, Erion Dobi, Thierry Nguyen, et al.
Oncotarget|November 22, 2018
Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatmentSindy Vrecko, David Guenat, Patricia Mercier-Letondal, et al.
Pharmaceutics|October 23, 2021
Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated PatientsAlexandre Le Marouille, Emma Petit, Courèche Kaderbhaï, et al.
Therapeutic Advances in Medical Oncology|January 16, 2023
Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patientsSidonie Callon, Mathias Brugel, Damien Botsen, et al.
Therapeutic Advances in Medical Oncology|April 26, 2024
Improving olaparib exposure to optimize adverse effects managementMarylise Sterlé, Alicja Puszkiel, Chloé Burlot, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Obesity (Silver Spring, Md.)|December 1, 2006
ABCA1 single nucleotide polymorphisms on high-density lipoprotein-cholesterol and overweight: the D.E.S.I.R. studyIsabelle Porchay, Franck Péan, Naïma Bellili, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2021
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patientsNastja Lunar, Marie-Christine Etienne-Grimaldi, Pauline Macaire, et al.
Anti-Cancer Drugs|September 16, 2005
Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein bindingBernard Royer, Emmanuel Guardiola, Emmanuel Polycarpe, et al.
Anti-Cancer Drugs|December 25, 2009
Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I studyEmmanuel Guardiola, Bruno Chauffert, Delphine Delroeux, et al.
Seminars in Oncology|September 20, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincingMarie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, et al.
Anti-Cancer Drugs|September 22, 2010
Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumorsAntoine Thiery-Vuillemin, Erion Dobi, Thierry Nguyen, et al.
Oncotarget|November 22, 2018
Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatmentSindy Vrecko, David Guenat, Patricia Mercier-Letondal, et al.
Pharmaceutics|October 23, 2021
Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated PatientsAlexandre Le Marouille, Emma Petit, Courèche Kaderbhaï, et al.
Therapeutic Advances in Medical Oncology|January 16, 2023
Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patientsSidonie Callon, Mathias Brugel, Damien Botsen, et al.
Therapeutic Advances in Medical Oncology|April 26, 2024
Improving olaparib exposure to optimize adverse effects managementMarylise Sterlé, Alicja Puszkiel, Chloé Burlot, et al.
Pageof 7